ArticleTuberculosis and respiratory diseases2025
Korean Guidelines for the Diagnosis and Management of Interstitial Lung Diseases: Hypersensitivity Pneumonitis.
Article in Tuberculosis and respiratory diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity pneumonitis (HP) is characterized as an immune-mediated interstitial lung disease with heterogeneous clinical manifestations and presents complex diagnostic challenges. This clinical guideline provides a comprehensive framework for diagnosing and managing HP, accentuating the evolving classification into fibrotic and nonfibrotic subtypes. By integrating current clinical guidelines and expert consensus, it addresses essential aspects such as radiologic and histopathologic findings, diagnostic strategies, and pharmacologic management. Tailored to the healthcare context in Korea, this guideline presents clinicians with a structured approach to diagnose and manage HP, considering regional variations in antigen exposure and clinical presentation. The recommendations are based on both international and local data, aiming to enhance outcomes for Korean patients through timely and accurate diagnosis, individualized treatment plans, and meticulous monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.